{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:43:58Z","timestamp":1793598238782,"version":"4.5.0"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,18]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Nonalcoholic steatohepatitis is regarded as a risk factor of many liver diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Relevant studies were searched from The National Library of Medicine, Cochrane Library, Elsevier, China National Knowledge Infrastructure, Web of Science and WANFANG databases. A total of 15 eligible studies were analyzed in the Reviewer Manager 5.3 software, including 7 English articles and 8 Chinese articles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Fifteen studies are selected for this meta-analysis, which includes totally 623 patients in the treatment group and 594 patients in the control group. As a result, 8 studies show that the total effective rate of the treatment group is higher than that of the control group [\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20053.64, 95% confidence intervals (CI): 1.78 (1.31\u20132.43),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0003]; eleven studies show that fasting plasma glucose levels of the experimental group are lower than that of the control group [\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20054.38, 95% CI: \u22120.95 (\u22121.38 to \u22120.53),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.0001]; ten studies show that glutamic-pyruvic transaminase levels of the experimental group are lower than that of the control group [\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20053.69, 95% CI: \u221211.76 (\u221218.01 to \u22125.51),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0002]; 6 studies show that glutamic oxalacetic transaminase levels of the experimental group are lower than that of the control group [\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20057.40, 95% CI: \u22123.01 (\u22123.81 to \u22122.22),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.00001]; 6 studies show that gamma-glutamyl transpeptidase levels of the experimental group are lower than that of the control group [\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20052.43, 95% CI: \u221223.77 (\u221242.98 to \u22124.57),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.02]; 9 studies show that triglyceride levels of the experimental group are lower than that of the control group [\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20053.06, 95% CI: \u22120.62 (\u22121.01 to \u22120.22),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.002]; 6 studies show that the homeostasis model assessment of insulin resistance of the experimental group is lower than that of the control group [\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20053.22, 95% CI: \u22122.33 (\u22123.75 to \u22120.91),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.001]; 6 studies show that the glycated hemoglobin A1c of the experimental group is lower than that of the control group [\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20054.50, 95% CI: \u22121.90 (\u22122.72 to \u22121.07),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.00001]; five studies show that the fasting insulin of the experimental group is lower than that of the control group [\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u2005=\u20053.42, 95% CI: \u22122.25 (\u22123.53 to \u22120.96),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0006].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Pioglitazone intake is effective in nonalcoholic steatohepatitis management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000031508","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T17:05:14Z","timestamp":1669827914000},"page":"e31508","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":32,"title":["Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs"],"prefix":"10.1097","volume":"101","author":[{"given":"Yan","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Public Health, International College, Krirk University, Bangkok, Thailand"},{"name":"Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Public Health, International College, Krirk University, Bangkok, Thailand"},{"name":"Liver Center, Saga University Hospital, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwu","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Health science and Engineering, Tianjin University of Traditional Chinese Medicine, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Public Health, International College, Krirk University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaien","family":"Bu","sequence":"additional","affiliation":[{"name":"School of Health Science and Engineering, Tianjin University of Traditional Chinese Medicine, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Liver Center, Saga University Hospital, Faculty of Medicine, Saga University, Saga, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review.","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/ijms17091575","article-title":"Molecular pathogenesis of NASH.","volume":"17","author":"Caligiuri","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.2174\/13816128113199990344","article-title":"Pathophysiology of NASH: perspectives for a targeted treatment.","volume":"19","author":"Marra","year":"2013","journal-title":"Curr Pharm Des"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/hep.28392","article-title":"Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice.","volume":"63","author":"Marchesini","year":"2016","journal-title":"Hepatology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2174\/138161210791208875","article-title":"Insulin resistance in nonalcoholic fatty liver disease.","volume":"16","author":"Bugianesi","year":"2010","journal-title":"Curr Pharm Des"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrm2391","article-title":"Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.","volume":"9","author":"Guilherme","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of nonalcoholic steatohepatitis.","volume":"150","author":"Machado","year":"2016","journal-title":"Gastroenterology"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cld.2009.07.009","article-title":"Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis.","volume":"13","author":"Cusi","year":"2009","journal-title":"Clin Liver Dis"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"581","DOI":"10.5650\/jos.ess19018","article-title":"Hepatoprotective effect of seed coat of euryale ferox extract in non-alcoholic fatty liver disease induced by high-fat diet in mice by increasing IRs-1 and inhibiting CYP2E1.","volume":"68","author":"Jian","year":"2019","journal-title":"J Oleo Sci"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1053\/j.gastro.2007.10.039","article-title":"Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease.","volume":"134","author":"Puri","year":"2008","journal-title":"Gastroenterology"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2010.11.005","article-title":"Endoplasmic reticulum stress in liver disease.","volume":"54","author":"Malhi","year":"2011","journal-title":"J Hepatol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in NAFLD - Revisited after a decade.","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.cell.2010.02.034","article-title":"Endoplasmic reticulum stress and the inflammatory basis of metabolic disease.","volume":"140","author":"Hotamisligil","year":"2010","journal-title":"Cell"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1478-3231.2008.01723.x","article-title":"Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis.","volume":"28","author":"Farhadi","year":"2008","journal-title":"Liver Int"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH.","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/hep.27982","article-title":"CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: limiting steatohepatitis by maintaining intestinal homeostasis.","volume":"62","author":"Schneider","year":"2015","journal-title":"Hepatology"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1053\/j.gastro.2016.06.022","article-title":"Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol.","volume":"151","author":"Rahman","year":"2016","journal-title":"Gastroenterology"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/17474124.2017.1293523","article-title":"Current and future treatment options in non-alcoholic steatohepatitis (NASH).","volume":"11","author":"Lazaridis","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH.","volume":"53","author":"Sumida","year":"2018","journal-title":"J Gastroenterol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise.","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1126\/science.3303333","article-title":"Fish oil prevents insulin resistance induced by high-fat feeding in rats.","volume":"237","author":"Storlien","year":"1987","journal-title":"Science"},{"key":"R22-20250504","first-page":"1529","article-title":"Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression.","volume":"38","author":"Sekiya","year":"2003","journal-title":"Hepatology"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ajcn\/77.5.1146","article-title":"Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials.","volume":"77","author":"Mensink","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: a stage-based approach.","volume":"13","author":"Rinella","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/hep.27544","article-title":"Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study.","volume":"61","author":"Oh","year":"2015","journal-title":"Hepatology"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients.","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jceh.2019.06.003","article-title":"Antidiabetic drugs and statins in nonalcoholic fatty liver disease.","volume":"9","author":"Kothari","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2036.2010.04405.x","article-title":"Pioglitazone in the treatment of NASH: the role of adiponectin.","volume":"32","author":"Gastaldelli","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/1753-0407.12833","article-title":"Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: a 36-month clinical trial.","volume":"11","author":"Portillo-Sanchez","year":"2019","journal-title":"J Diabetes"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2007.04.013","article-title":"Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis.","volume":"47","author":"Balas","year":"2007","journal-title":"J Hepatol"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"R35-20250504","first-page":"434","article-title":"Safety and effectiveness of pioglitazone in the treatment of non-alcoholic fatty liver disease.","volume":"23","author":"Xiang","year":"2007","journal-title":"Chin J Clin Hepatol"},{"key":"R36-20250504","first-page":"304","article-title":"Efficacy and safety of pioglitazone in the treatment of nonalcoholic fatty liver disease.","volume":"17","author":"Chen","year":"2018","journal-title":"Health Guide"},{"key":"R37-20250504","first-page":"379","article-title":"Effect of piglitazone on plasma leptin and insulin resistance in patients with IGT complicated by nonalcoholic fatty liver.","volume":"42","author":"Guo","year":"2014","journal-title":"Med Sci J Central South China"},{"key":"R38-20250504","first-page":"5","article-title":"The effect of pioglitazone on serum adiponerctin levels in patients with impaired glucose tolerance with non \u2013 alcoholic fatty liver. Liaocheng Second People\u2019s Hospital of Shandong Province.","volume":"35","author":"He","year":"2008","journal-title":"Central Plains Med J"},{"key":"R39-20250504","first-page":"221","article-title":"Efficacy of pioglitazone in treatment of 60 patients with nonalcoholic steatohepatitis.","volume":"10","author":"Jin","year":"2010","journal-title":"Pharm Care Res"},{"key":"R40-20250504","first-page":"4454","article-title":"Efficacy of pioglitazone and metformin in the treatment of newly diagnosed type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease.","volume":"34","author":"Li","year":"2014","journal-title":"Chin J Gerontol"},{"key":"R41-20250504","first-page":"1349","article-title":"Effect of pioglitazone on plasma homocysteine level in patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease.","volume":"24","author":"Xiang","year":"2009","journal-title":"Clin Focus"},{"key":"R42-20250504","first-page":"776","article-title":"Therapeutic efficacy of pioglitazone combined with non-drug treatment on nonalcoholic fatty liver disease.","volume":"32","author":"Xie","year":"2014","journal-title":"J Guangdong Med College"},{"key":"R43-20250504","first-page":"379","article-title":"Pioglitazone.","volume":"41","author":"Al-Majed","year":"2016","journal-title":"Prof Drug Subs Exc Rel Methodol"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2337\/db07-0827","article-title":"Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.","volume":"57","author":"Basu","year":"2008","journal-title":"Diabetes"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"8748","DOI":"10.1074\/jbc.M505649200","article-title":"Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.","volume":"281","author":"Kubota","year":"2006","journal-title":"J Biol Chem"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijrobp.2006.09.036","article-title":"Administration of the peroxisomal proliferator-activated receptor gamma agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment.","volume":"67","author":"Zhao","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijcard.2013.12.289","article-title":"Change in serum PEDF level after pioglitazone treatment is independently correlated with that in HOMA-IR.","volume":"172","author":"Tahara","year":"2014","journal-title":"Int J Cardiol"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"6489012","DOI":"10.1155\/2016\/6489012","article-title":"Role of NLRP3 inflammasome in the progression of NAFLD to NASH.","volume":"2016","author":"Wan","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites.","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"R50-20250504","first-page":"612","article-title":"Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke.","volume":"13","author":"Sacks","year":"2018","journal-title":"Int J Stroke"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1053\/j.gastro.2008.12.064","article-title":"Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis.","volume":"136","author":"Kodama","year":"2009","journal-title":"Gastroenterology"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.","volume":"39","author":"Promrat","year":"2004","journal-title":"Hepatology"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0148607113501201","article-title":"The effect of a low fructose and low glycemic index\/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD).","volume":"39","author":"Mager","year":"2015","journal-title":"J Parenter Enteral Nutr"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12967-018-1657-6","article-title":"Joint associations of serum uric acid and ALT with NAFLD in elderly men and women: a Chinese cross-sectional study.","volume":"16","author":"Yang","year":"2018","journal-title":"J Transl Med"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3390\/nu10091329","article-title":"Non-alcoholic fatty liver disease in overweight children: role of fructose intake and dietary pattern.","volume":"10","author":"Nier","year":"2018","journal-title":"Nutrients"},{"issue":"1 Suppl 1","key":"R56-20250504","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.dsx.2015.09.005","article-title":"Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adults: association of GGT and HOMA-IR with NAFLD.","volume":"10","author":"Hossain","year":"2016","journal-title":"Diabetes Metab Syndr"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(16)30011-5","article-title":"Pathogenesis and novel treatment options for non-alcoholic steatohepatitis.","volume":"1","author":"Wong","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/hep.21661","article-title":"The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.","volume":"46","author":"Lutchman","year":"2007","journal-title":"Hepatology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:04:40Z","timestamp":1746320680000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":58,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031508","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]}}}